Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TUKTY
ADC Name	PRO-1184
Synonyms	PRO 1184; PRO1184 Click to Show/Hide
Organization	ProfoundBio (Suzhou) Co., Ltd.
Drug Status	Phase 1/2
Indication	In total 10 Indication(s) Endometrial cancer [ICD11:2C76] Phase 2 Fallopian tube cancer [ICD11:2C74] Phase 2 HER2(+) breast cancer [ICD11:2C60-2C65] Phase 2 HER2(-) breast cancer [ICD11:2C60-2C65] Phase 2 Non-small cell lung cancer [ICD11:2C25] Phase 2 Ovarian cancer [ICD11:2C73] Phase 2 Peritoneal cancer [ICD11:2C51] Phase 2 Pleural mesothelioma [ICD11:2C26] Phase 2 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 2 Triple negative breast cancer [ICD11:2C60-2C65] Phase 2
Drug-to-Antibody Ratio	8
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Folate receptor alpha (FOLR1)		Antigen Info
Payload Name	Exatecan		Payload Info
Therapeutic Target	DNA topoisomerase 1 (TOP1)		Target Info
Linker Name	Cys-11 ADC linker		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	LD038

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05579366	Phase 1/2	Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05579366	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.

References

Ref 1	Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors, NCT05579366